On paper, Melanotan 1 and Melanotan 2 look like siblings. Both are synthetic analogs of α-melanocyte-stimulating hormone (α-MSH), both are studied for their effects on pigmentation, and both have names that differ by a single digit. That similarity is exactly why they are so often conflated in casual discussion. But in the research literature the two compounds diverge in a way that matters a great deal: receptor selectivity. Understanding that single distinction explains almost everything else about how their preclinical and clinical profiles differ.
This article compares the two on mechanism, structure, and pharmacokinetics only. It is written for the laboratory research community and makes no recommendations for use.
The melanocortin system in one paragraph
Both peptides act on the melanocortin receptor family, a set of five G-protein-coupled receptors (MC1R through MC5R) that respond to melanocortin ligands derived from the precursor protein POMC. The receptors are distributed across very different tissues. MC1R sits on melanocytes and drives melanogenesis — the production of eumelanin pigment. MC3R and MC4R are concentrated in the central nervous system and are studied in the context of energy balance, appetite, and sexual function. MC5R is linked to exocrine gland activity. Because these receptors govern such different physiology, a ligand's behavior depends enormously on which receptors it engages and how strongly. For a fuller treatment of this pathway, see our library.
The endogenous ligand α-MSH is relatively short-lived and not strongly selective. The Melanotan compounds were designed in the 1980s at the University of Arizona to be more potent and more metabolically stable than the native hormone.
Melanotan 1: the more selective analog
Melanotan 1, also known by its International Nonproprietary Name afamelanotide, is a linear 13-amino-acid peptide. Structurally it is [Nle⁴, D-Phe⁷]-α-MSH — the native α-MSH sequence with two substitutions: norleucine replacing methionine at position 4, and a D-isomer of phenylalanine at position 7. Those two changes dramatically increase resistance to enzymatic degradation and boost potency relative to α-MSH while keeping the peptide's overall shape close to the parent hormone.
In the research framing, Melanotan 1 is generally described as the more melanogenesis-focused of the two. Its activity profile has made it the basis of the only melanocortin analog in this pair to reach regulatory approval: afamelanotide is marketed as a slow-release subcutaneous implant studied and approved for erythropoietic protoporphyria (EPP), a rare photosensitivity disorder, where increased eumelanin offers photoprotection. That clinical development program means Melanotan 1 has a comparatively well-characterized safety and pharmacology dataset behind it.
The trade-off is that its activity is weighted toward pigmentation pathways and it does not produce the broad central effects associated with strong MC4R engagement.
Melanotan 2: the nonselective agonist
Melanotan 2 is a different molecule despite the similar name. It is a cyclic heptapeptide — a smaller, ring-shaped structure formed by a lactam bridge — rather than a linear 13-mer. That cyclization was introduced specifically to improve stability and potency, and it produced a compound that behaves as a broad, nonselective melanocortin agonist, activating MC1R, MC3R, MC4R and MC5R.
This is the crux of the comparison. Because Melanotan 2 engages MC4R in addition to MC1R, the preclinical literature associated with it extends beyond pigmentation into MC4R-mediated physiology: appetite/energy balance and, most notably, sexual-arousal pathways. The erectogenic and libido-related observations reported in early human and animal studies of Melanotan 2 trace back to this central MC4R activity — something the more selective Melanotan 1 is not primarily noted for.
It was precisely this dual character that motivated medicinal chemists to carve out a more MC4R-selective fragment from the Melanotan 2 scaffold. That effort produced bremelanotide, studied specifically for sexual-function endpoints — available in the catalog as PT-141. In other words, Melanotan 2's nonselectivity is both the source of its broad research interest and the reason researchers eventually wanted a cleaner tool.
Side-by-side: structure, selectivity, profile
| Feature | Melanotan 1 (afamelanotide) | Melanotan 2 |
|---|---|---|
| Structure | Linear 13-aa peptide | Cyclic 7-aa peptide (lactam bridge) |
| Sequence basis | [Nle⁴, D-Phe⁷]-α-MSH | Truncated, cyclized α-MSH analog |
| Receptor profile | Broad agonist, research interest weighted toward MC1R / melanogenesis | Nonselective agonist (MC1R, MC3R, MC4R, MC5R) |
| Primary research association | Pigmentation; photoprotection (EPP) | Pigmentation plus MC4R-mediated effects (appetite, sexual arousal) |
| Regulatory status | Approved as afamelanotide (Scenesse) for EPP | No approved formulation; research compound |
| Related catalog compound | — | PT-141 (MC4R-selective derivative) |
The catalog lists both as Melanotan 1 and Melanotan 2.
Pharmacokinetics and stability
Both peptides were engineered to outlast the native hormone, but their delivery contexts differ in the literature. Melanotan 1 / afamelanotide is most characterized as a sustained-release subcutaneous implant, a formulation designed to release the peptide gradually over a period of days — the relevant pharmacokinetic parameter in that clinical setting is the controlled-release profile of the implant rather than the free peptide's intrinsic half-life, which is short.
Melanotan 2 has a comparatively short circulating half-life in the research literature, generally reported on the order of an hour or so, reflecting its small cyclic structure. Precise published human PK values for Melanotan 2 are limited, since it never advanced through a formal clinical development program; much of what is cited derives from early-phase and preclinical work. Researchers should treat any single half-life figure for Melanotan 2 with caution and consult primary sources.
As lyophilized powders, both are typically handled like other research peptides — kept cold and protected from light and moisture. Our quality page covers general peptide handling and storage principles, and the identity/purity testing that distinguishes a 13-mer linear peptide from a cyclic 7-mer on analytical readouts.
Why the "1 vs 2" framing can mislead
The shared name invites the assumption that Melanotan 2 is simply a "version 2" or an upgrade of Melanotan 1. It is not. They are distinct molecules of different size and shape, designed with different goals, and their research profiles diverge because their receptor selectivity diverges. Melanotan 1 is the narrower, better-validated tool oriented toward melanogenesis; Melanotan 2 is the broader, nonselective agonist whose MC4R activity opened up adjacent research questions — questions later pursued with the more selective PT-141.
For researchers, the practical takeaway is that selecting between them is a question of which receptors the experiment intends to probe, not which is "stronger" in the abstract.
FAQ
Are Melanotan 1 and Melanotan 2 the same peptide at different doses? No. They are structurally different molecules — a linear 13-amino-acid peptide versus a cyclic 7-amino-acid peptide — with different receptor-binding profiles.
Which one is approved as a drug? Melanotan 1, under the name afamelanotide, has an approved sustained-release implant formulation studied for erythropoietic protoporphyria. Melanotan 2 has no approved formulation and is a research compound.
How does PT-141 relate to these two? PT-141 (bremelanotide) was derived from the Melanotan 2 scaffold and is more selective for the MC4R/MC1R pathway studied in the context of sexual function.
This article is educational and for the laboratory research community. Trulogic Labs products are sold for laboratory and research use only and are not for human consumption.